Meda acquired global rights to MUSE (transurethral alprostadil), a well established product for the treatment of erectile dysfunction.
Meda has had the distribution rights to MUSE in Europe for many years. Meda will now take over global rights and all assets relating to the product. The largest market is the US where annual sales are approximately 15 MUSD.
The acquisition price is an upfront payment of 22 MUSD and a potential sales milestone payment of 1,5 MUSD based on future sales of MUSE. The transaction is subject to standard closing requirements. The transaction is expected to close within 60 days.